Amygdala Neurosciences Wins FDA Clearance to Test ANS-858 for Alcohol and Substance Use Disorders

The U.S. Food and Drug Administration has cleared the Investigational New Drug application for ANS-858, a novel therapeutic candidate targeting pathological craving in alcohol use disorder and other substance use disorders, enabling Palo Alto-based Amygdala Neurosciences to advance into Phase 1 clinical trials.

ANS-858 represents a new mechanistic approach to addiction treatment. The drug is a selective, reversible, orally bioavailable inhibitor of ALDH2, an enzyme that Amygdala's research has identified as an important regulator of pathological craving. By modulating this biological pathway, the company believes ANS-858 can reduce the intense cravings that drive substance use and relapse, addressing a core challenge in addiction recovery.

How ALDH2 Inhibition Targets Craving

The therapeutic rationale for ANS-858 builds upon human genetic and clinical evidence linking reduced ALDH2 activity with decreased alcohol consumption. ALDH2 plays a central role in alcohol metabolism, but Amygdala's research has revealed its broader function in regulating the biological mechanisms underlying pathological craving across multiple substances.

"Our research has demonstrated the important role of ALDH2 in pathological craving and led to the development of selective inhibitors designed to translate this biology into novel therapeutic approaches," said Brent Blackburn, Ph.D., Chief Executive Officer of Amygdala Neurosciences, in a statement announcing the IND clearance.

The company's platform represents what it believes are the first and only known selective, orally bioavailable, once-daily inhibitors of ALDH2, protected by composition-of-matter intellectual property.

Clinical Development Plans

With FDA clearance in hand, Amygdala Neurosciences plans to initiate a Phase 1 clinical trial designed to support subsequent evaluation of ANS-858 across multiple indications in Phase 2 studies. The initial focus is on alcohol use disorder, where existing medications such as naltrexone, acamprosate, and disulfiram help some patients but leave significant unmet need.

The National Institute on Alcohol Abuse and Alcoholism estimates that approximately 29.5 million Americans had alcohol use disorder in 2023, yet only a small fraction receive pharmacological treatment. Current medications work through different mechanisms than ALDH2 inhibition, suggesting ANS-858 could offer a genuinely additive therapeutic option rather than simply competing in an existing category.

Broader Therapeutic Applications

Beyond alcohol and substance use disorders, Amygdala is evaluating ANS-858 in compulsive eating disorders associated with binge eating and obesity. The company notes biological similarities between the mechanisms underlying pathological food craving and those involved in substance use disorders.

In this context, ANS-858 has the potential to be developed as a once-daily oral therapy to reduce pathological food cravings and support long-term weight management, either as a standalone treatment or as an adjunct to GLP-1 receptor agonists, the drug class that includes semaglutide.

Additionally, Amygdala Neurosciences is exploring its proprietary library of selective ALDH2 inhibitors in precision oncology, particularly for colorectal cancers harboring APC mutations, which are present in approximately 70% of colorectal cancer cases.

Research Foundation and Funding

The discovery and development of ANS-858 have been supported by NIH grants R43AA029311 and U43AA030689, as well as investment from ABMRF/The Foundation for Alcohol Research. Amygdala Neurosciences notes that the content of its research is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

The company is led by an experienced team of scientist-entrepreneurs with a track record of developing and commercializing novel therapeutics, including Ranexa and Lexiscan. Blackburn previously led Research and Development at CV Therapeutics and founded Rapiscan Pharma Solutions, which was acquired by GE Healthcare.

The Regulatory Path Ahead

IND clearance represents a significant milestone, but the path to FDA approval for addiction medications remains rigorous. ANS-858 is investigational and has not been approved by the FDA or any other regulatory authority. Phase 1 trials will assess safety, tolerability, and pharmacokinetics before the drug can advance to efficacy studies.

For people currently seeking help for alcohol or substance use disorders, medication-assisted treatment programs using existing FDA-approved medications remain the standard of care. These programs combine pharmacological support with behavioral therapy and peer support to address the complex biological and psychological dimensions of addiction.

The FDA's clearance of the ANS-858 IND adds to a growing pipeline of novel therapeutic approaches targeting addiction through previously unexplored biological mechanisms, offering hope that the limited pharmacological toolkit available to addiction medicine specialists may expand in the coming years.